Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartan

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.11, Iss.9, 2010-06, pp. : 1549-1558

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Relationship between the Frequency of Blood Pressure Self-Measurement and Blood Pressure Reduction with Antihypertensive Therapy: Results of the OLMETEL (OLMEsartan TELemonitoring Blood Pressure) Study

By Ewald Silke

Clinical Drug Investigation, Vol. 26, Iss. 8, 2006-01 ,pp. : 439-446

Adis International

Access to resources Recommend Favorite

Olmesartan Medoxomil-Based Antihypertensive Therapy Evaluated by Ambulatory Blood Pressure Monitoring: Efficacy in High-Risk Patient Subgroups

By Chrysant Steven G.

American Journal of Cardiovascular Drugs, Vol. 12, Iss. 6, 2012-12 ,pp. : 375-389

Adis International

Access to resources Recommend Favorite

Effective Systolic Blood Pressure Reduction with Olmesartan Medoxomil/Amlodipine Combination Therapy: Post Hoc Analysis of Data from a Randomized, Double-Blind, Parallel-Group, Multicentre Study

By Mourad Jean-Jacques >

Clinical Drug Investigation, Vol. 29, Iss. 6, 2009-05 ,pp. : 419-425

Adis International

Access to resources Recommend Favorite

Antihypertensive Efficacy of Olmesartan Medoxomil and Candesartan Cilexetil in Achieving 24-Hour Blood Pressure Reductions and Ambulatory Blood Pressure Goals

By Brunner Hans R.

Clinical Drug Investigation, Vol. 26, Iss. 4, 2006-01 ,pp. : 185-193

Adis International

Access to resources Recommend Favorite

Cardiovascular risk reduction targets in diabetes

Inpharma, Vol. 1, Iss. 1430, 2004-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite